biogen idec research limited Company Information
Company Number
07588215
Next Accounts
Sep 2025
Shareholders
biogen ma inc.
Group Structure
View All
Industry
Other research and experimental development on natural sciences and engineering
Registered Address
building 5 foundation park, roxborough way, maidenhead, berkshire, SL6 3UD
Website
www.biogen.uk.combiogen idec research limited Estimated Valuation
Pomanda estimates the enterprise value of BIOGEN IDEC RESEARCH LIMITED at £6.2k based on a Turnover of £7.8k and 0.8x industry multiple (adjusted for size and gross margin).
biogen idec research limited Estimated Valuation
Pomanda estimates the enterprise value of BIOGEN IDEC RESEARCH LIMITED at £3.7k based on an EBITDA of £1k and a 3.65x industry multiple (adjusted for size and gross margin).
biogen idec research limited Estimated Valuation
Pomanda estimates the enterprise value of BIOGEN IDEC RESEARCH LIMITED at £627.2k based on Net Assets of £308.4k and 2.03x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Biogen Idec Research Limited Overview
Biogen Idec Research Limited is a live company located in maidenhead, SL6 3UD with a Companies House number of 07588215. It operates in the other research and experimental development on natural sciences and engineering sector, SIC Code 72190. Founded in April 2011, it's largest shareholder is biogen ma inc. with a 100% stake. Biogen Idec Research Limited is a established, micro sized company, Pomanda has estimated its turnover at £7.8k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Biogen Idec Research Limited Health Check
Pomanda's financial health check has awarded Biogen Idec Research Limited a 3.5 rating. We use a traffic light system to show it exceeds the industry average on 3 measures and has 5 areas for improvement. Company Health Check FAQs


3 Strong

0 Regular

5 Weak

Size
annual sales of £7.8k, make it smaller than the average company (£4.3m)
£7.8k - Biogen Idec Research Limited
£4.3m - Industry AVG

Growth
3 year (CAGR) sales growth of -3%, show it is growing at a slower rate (6.8%)
-3% - Biogen Idec Research Limited
6.8% - Industry AVG

Production
with a gross margin of 13%, this company has a higher cost of product (46.9%)
13% - Biogen Idec Research Limited
46.9% - Industry AVG

Profitability
an operating margin of 13% make it more profitable than the average company (3.6%)
13% - Biogen Idec Research Limited
3.6% - Industry AVG

Employees
with 2 employees, this is below the industry average (44)
2 - Biogen Idec Research Limited
44 - Industry AVG

Pay Structure
There is insufficient data available for this Key Performance Indicator!
- - Biogen Idec Research Limited
- - Industry AVG

Efficiency
resulting in sales per employee of £3.9k, this is less efficient (£124k)
£3.9k - Biogen Idec Research Limited
£124k - Industry AVG

Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Biogen Idec Research Limited
- - Industry AVG

Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Biogen Idec Research Limited
- - Industry AVG

Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Biogen Idec Research Limited
- - Industry AVG

Cash Balance
has cash to cover current liabilities for 9869 weeks, this is more cash available to meet short term requirements (32 weeks)
9869 weeks - Biogen Idec Research Limited
32 weeks - Industry AVG

Debt Level
it has a ratio of liabilities to total assets of 0.5%, this is a lower level of debt than the average (44.4%)
0.5% - Biogen Idec Research Limited
44.4% - Industry AVG
BIOGEN IDEC RESEARCH LIMITED financials

Biogen Idec Research Limited's latest turnover from December 2023 is £7.8 thousand and the company has net assets of £308.4 thousand. According to their latest financial statements, Biogen Idec Research Limited has 2 employees and maintains cash reserves of £284.5 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | 7,789 | 7,664 | 7,688 | 8,525 | 9,295 | 18,959 | 72,620 | 527,853 | 1,188,252 | 807,317 | 1,025,661 | 900,630 | 424,285 |
Other Income Or Grants | |||||||||||||
Cost Of Sales | 6,778 | 11,598 | |||||||||||
Gross Profit | 1,011 | -3,934 | |||||||||||
Admin Expenses | |||||||||||||
Operating Profit | 1,011 | -3,934 | -4,014 | 3,222 | -3,664 | -9,441 | 3,319 | 10,225 | 112,669 | 71,212 | 88,125 | 66,633 | 39,500 |
Interest Payable | |||||||||||||
Interest Receivable | 6,879 | 1,040 | |||||||||||
Pre-Tax Profit | 7,890 | -2,894 | -4,014 | 3,222 | -3,664 | -9,441 | 3,319 | 10,225 | 112,669 | 71,212 | 88,125 | 66,633 | 39,500 |
Tax | 14,404 | -17,450 | -68,654 | -26,683 | -780 | -10,269 | |||||||
Profit After Tax | 7,890 | -2,894 | -4,014 | 3,222 | -3,664 | 4,964 | 3,319 | 10,225 | 95,219 | 2,558 | 61,442 | 65,853 | 29,230 |
Dividends Paid | |||||||||||||
Retained Profit | 7,890 | -2,894 | -4,014 | 3,222 | -3,664 | 4,964 | 3,319 | 10,225 | 95,219 | 2,558 | 61,442 | 65,853 | 29,230 |
Employee Costs | |||||||||||||
Number Of Employees | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 4 | 5 | 5 | 5 |
EBITDA* | 1,011 | -3,934 | -4,014 | 3,222 | -3,664 | -9,441 | 3,319 | 10,225 | 112,669 | 71,212 | 88,125 | 66,633 | 39,500 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | |||||||||||||
Intangible Assets | |||||||||||||
Investments & Other | |||||||||||||
Debtors (Due After 1 year) | |||||||||||||
Total Fixed Assets | |||||||||||||
Stock & work in progress | |||||||||||||
Trade Debtors | |||||||||||||
Group Debtors | 25,371 | 25,806 | 25,136 | 37,191 | 15,795 | 14,091 | 67,874 | 200,463 | 483,241 | 180,741 | 131,040 | 145,668 | 424,285 |
Misc Debtors | 1,061 | 1,068 | 1,190 | 1,904 | 2,082 | 7,050 | |||||||
Cash | 284,498 | 276,173 | 281,619 | 309,232 | 268,268 | 300,441 | 294,718 | 286,181 | 249,793 | 187,122 | 168,466 | 96,910 | |
misc current assets | |||||||||||||
total current assets | 309,869 | 303,040 | 307,824 | 347,615 | 285,967 | 316,615 | 369,643 | 486,645 | 733,034 | 367,863 | 299,506 | 242,579 | 424,285 |
total assets | 309,869 | 303,040 | 307,824 | 347,615 | 285,967 | 316,615 | 369,643 | 486,645 | 733,034 | 367,863 | 299,506 | 242,579 | 424,285 |
Bank overdraft | |||||||||||||
Bank loan | |||||||||||||
Trade Creditors | 5,222 | 2,891 | |||||||||||
Group/Directors Accounts | 57,991 | 186,413 | 435,095 | 171,364 | 134,705 | 143,495 | 381,894 | ||||||
other short term finances | |||||||||||||
hp & lease commitments | |||||||||||||
other current liabilities | 1,498 | 5,136 | 9,598 | 4,937 | 2,700 | 10,269 | |||||||
total current liabilities | 1,499 | 57,991 | 191,549 | 444,693 | 176,301 | 137,405 | 148,717 | 395,055 | |||||
loans | |||||||||||||
hp & lease commitments | |||||||||||||
Accruals and Deferred Income | |||||||||||||
other liabilities | |||||||||||||
provisions | |||||||||||||
total long term liabilities | |||||||||||||
total liabilities | 1,499 | 57,991 | 191,549 | 444,693 | 176,301 | 137,405 | 148,717 | 395,055 | |||||
net assets | 308,370 | 303,040 | 307,824 | 347,615 | 285,967 | 316,615 | 311,652 | 295,095 | 288,341 | 191,562 | 162,101 | 93,862 | 29,230 |
total shareholders funds | 308,370 | 303,040 | 307,824 | 347,615 | 285,967 | 316,615 | 311,652 | 295,095 | 288,341 | 191,562 | 162,101 | 93,862 | 29,230 |
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | |||||||||||||
Operating Profit | 1,011 | -3,934 | -4,014 | 3,222 | -3,664 | -9,441 | 3,319 | 10,225 | 112,669 | 71,212 | 88,125 | 66,633 | 39,500 |
Depreciation | |||||||||||||
Amortisation | |||||||||||||
Tax | 14,404 | -17,450 | -68,654 | -26,683 | -780 | -10,269 | |||||||
Stock | |||||||||||||
Debtors | -1,496 | 663 | -12,178 | 20,683 | 1,526 | -58,752 | -125,538 | -282,778 | 302,500 | 49,701 | -14,628 | -278,617 | 424,285 |
Creditors | -5,222 | 2,331 | 2,891 | ||||||||||
Accruals and Deferred Income | 1,498 | -5,136 | -4,462 | 4,661 | 2,237 | 2,700 | -10,269 | 10,269 | |||||
Deferred Taxes & Provisions | |||||||||||||
Cash flow from operations | 4,005 | -4,597 | 8,164 | -17,461 | -5,190 | 63,715 | 123,721 | 288,541 | -202,620 | -44,906 | 73,548 | 336,532 | -381,894 |
Investing Activities | |||||||||||||
capital expenditure | |||||||||||||
Change in Investments | |||||||||||||
cash flow from investments | |||||||||||||
Financing Activities | |||||||||||||
Bank loans | |||||||||||||
Group/Directors Accounts | -57,991 | -128,423 | -248,682 | 263,731 | 36,659 | -8,791 | -238,399 | 381,894 | |||||
Other Short Term Loans | |||||||||||||
Long term loans | |||||||||||||
Hire Purchase and Lease Commitments | |||||||||||||
other long term liabilities | |||||||||||||
share issue | |||||||||||||
interest | 6,879 | 1,040 | |||||||||||
cash flow from financing | 4,319 | -849 | -35,777 | 58,425 | -26,984 | -57,991 | -115,186 | -252,152 | 265,291 | 63,561 | -1,993 | -239,621 | 381,894 |
cash and cash equivalents | |||||||||||||
cash | 8,325 | -5,446 | -27,613 | 40,965 | -32,174 | 5,724 | 8,537 | 36,388 | 62,671 | 18,656 | 71,555 | 96,910 | |
overdraft | |||||||||||||
change in cash | 8,325 | -5,446 | -27,613 | 40,965 | -32,174 | 5,724 | 8,537 | 36,388 | 62,671 | 18,656 | 71,555 | 96,910 |
biogen idec research limited Credit Report and Business Information
Biogen Idec Research Limited Competitor Analysis

Perform a competitor analysis for biogen idec research limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other micro companies, companies in SL6 area or any other competitors across 12 key performance metrics.
biogen idec research limited Ownership
BIOGEN IDEC RESEARCH LIMITED group structure
Biogen Idec Research Limited has no subsidiary companies.
Ultimate parent company
BIOGEN IDEC INC.
#0112285
BIOGEN MA INC
#0069488
2 parents
BIOGEN IDEC RESEARCH LIMITED
07588215
biogen idec research limited directors
Biogen Idec Research Limited currently has 2 directors. The longest serving directors include Dr John Way (Aug 2021) and Mr Geronimo Martinez (Sep 2023).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Dr John Way | England | 51 years | Aug 2021 | - | Director |
Mr Geronimo Martinez | England | 39 years | Sep 2023 | - | Director |
P&L
December 2023turnover
7.8k
+2%
operating profit
1k
-126%
gross margin
13%
-125.29%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
308.4k
+0.02%
total assets
309.9k
+0.02%
cash
284.5k
+0.03%
net assets
Total assets minus all liabilities
biogen idec research limited company details
company number
07588215
Type
Private limited with Share Capital
industry
72190 - Other research and experimental development on natural sciences and engineering
incorporation date
April 2011
age
14
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
December 2023
previous names
N/A
accountant
-
auditor
PRICEWATERHOUSECOOPERS LLP
address
building 5 foundation park, roxborough way, maidenhead, berkshire, SL6 3UD
Bank
BANK OF AMERICA
Legal Advisor
-
biogen idec research limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to biogen idec research limited.
biogen idec research limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for BIOGEN IDEC RESEARCH LIMITED. This can take several minutes, an email will notify you when this has completed.
biogen idec research limited Companies House Filings - See Documents
date | description | view/download |
---|